Crown Castle International Corp vs Medtronic PLC — how do they compare? Crown Castle International Corp trades at $73.79 (market cap $31.32B), while Medtronic PLC trades at $90.58 (market cap $114.45B). The key difference: Medtronic PLC is far larger — about 3.7× Crown Castle International Corp's market cap, and Crown Castle International Corp pays the higher dividend (5.77%). Which is the better fit depends on your goals.
| CCI | MDT | |
|---|---|---|
Market Cap | $31.32B | $114.45B |
Sector | Real Estate | Health |
52-Week High | $103.79 | $105.35 |
52-Week Low | $73.61 | $73.75 |
Enterprise Value | $53.68B | $133.19B |
Dividend Yield | 5.77% | 3.22% |
Signals from Pluang's Aura AI — not financial advice
Crown Castle (CCI) trades at $75.59, up 0.89% on the day, but technical indicators signal a bearish trend with the stock near recent lows. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, while revenue has declined from $7.0B in 2023 to $4.26B in 2025. Analyst consensus is split evenly between Buy and Hold with a $95.29 price target, suggesting potential upside. Recent news highlights strategic shifts, including the sale of its fiber business and a focus on U.S. tower operations.
The outlook for CCI hinges on execution of its pure-play tower strategy amid high debt levels and competitive pressures. Investment appeal lies in its 5.5% dividend yield and discounted valuation, but risks include declining revenue, negative shareholder equity, and sensitivity to interest rates. Wall Street sees value if operational improvements materialize.
Medtronic (MDT) trades at $87.16, up 1.44% today, with a bullish technical signal and consistent earnings beats. The company reported Q1 2026 EPS of $1.55, exceeding expectations, and maintains solid fundamentals with a 13.2% net income margin and $33.54B in revenue for 2025. Recent news highlights growth in cardiac ablation and the Hugo robotic platform, with management guiding for 11.75% organic revenue growth in Q1 2027.
The outlook is positive, supported by analyst consensus of a $98.75 price target and 60% buy ratings. Key opportunities include dividend stability and innovation in medical technology, while risks involve rising debt levels and competitive pressures. The stock's current valuation at a P/E of 23.37 offers moderate upside if execution continues.
Trailing returns across standard periods
Latest headlines on both assets
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →